Behind the 2025 ACC/AHA Acute Coronary Syndrome Guideline
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
Release Date: 09/02/2025
How Does Imaging Guide Management in Patients with Obesity?
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
Imaging is a powerful tool in managing obesity, helping clinicians visualize fat distribution and detect complications like fatty liver disease or heart issues. Advanced techniques like magnetic resonance imaging (MRI) and computed tomography (CT) scans guide personalized treatment plans and monitor progress over time. Despite challenges with equipment limitations, innovations like artificial intelligence and specialized scanners are making imaging more accessible and accurate for patients with obesity. In this interview, W. Douglas Weaver MD, MACC and Mouaz H. Al-Mallah, MD, FACC...
info_outline
TACSI Trial: Dual or Single Antiplatelet Therapy After CABG in Patients With ACS
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
In the TACSI trial, researchers evaluated ticagrelor plus aspirin versus aspirin alone in about 2,200 patients who underwent coronary artery bypass grafting (CABG) for acute coronary syndrome (ACS). At 12 months, dual antiplatelet therapy (DAPT) did not reduce major adverse cardiac events compared to aspirin alone. However, it was associated with a higher risk of major bleeding. These findings do not support routine DAPT use post-CABG in ACS patients, though longer-term follow-up is still needed. In this interview, Drs. Steven E. Nissen and Anders Jeppsson...
info_outline
VICTORION-Difference: Inclisiran-Based Strategy vs. Standard of Care
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
Current clinical challenges in lipid control include achieving and maintaining target LDL-cholesterol levels in patients at high risk for atherosclerotic cardiovascular disease, especially those who do not respond adequately to standard therapies. The VICTORION-Difference trial demonstrated that an inclisiran-based treatment strategy significantly outperformed usual care in helping patients reach early and sustained LDL-C goals. This approach also resulted in fewer muscle-related side effects, a common barrier to adherence. Inclisiran offers a...
info_outline
Aortopathies: What A Cardiologist Needs to Know
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
What if your genes could predict a life-threatening condition before symptoms ever appear? Explore how medical science uncovered the genetic roots of thoracic aortic aneurysm—and why that discovery changed everything. From famous historical figures to modern patients, the implications are profound: understanding the exact genetic mutation can guide treatment and safeguard entire families. In this interview, Drs. Jeroen J. Bax and John A. Elefteriades discuss “Aortopathies: What A Cardiologist Needs to Know”.
info_outline
PhysioSync-HF: Conduction System vs. Biventricular Pacing in Cardiac Resynchronization in HFrEF
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
Can a newer, more targeted pacing method revolutionize heart failure treatment? The PhysioSync-HF trial investigates conduction system pacing as a potentially more effective and affordable alternative to traditional cardiac resynchronization therapy. Explore the surprising differences between this study and prior research and hear firsthand what it was like to lead a nationwide, publicly funded clinical trial across Brazil. This episode dives deep into innovation, equity, and the future of heart care. In this interview, Drs. Joseph Marine and André Zimerman discuss...
info_outline
DAPT-SHOCK-AMI Trial: Cangrelor in Cardiogenic Shock
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
The DAPT SHOCK AMI trial is the first major study to evaluate antiplatelet therapy specifically in patients with cardiogenic shock (CS) following acute myocardial infarction (AMI). It compares initial treatment strategies using cangrelor versus crushed ticagrelor. Early and potent platelet inhibition is critical for restoring microvascular reperfusion in this high-risk population. Previous randomized trials have excluded these patients, leaving a gap in evidence for optimal antiplatelet management in AMI-CS. In this interview, Drs. Dipti Itchhaporia and Zuzana Motovska...
info_outline
ODYSSEY-HCM: Mavacamten in nHCM
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
The ODYSSEY-HCM trial found that mavacamten did not significantly improve exercise capacity or patient-reported outcomes in individuals with symptomatic nonobstructive hypertrophic cardiomyopathy. Safety concerns emerged, including more frequent reductions in ejection fraction and treatment interruptions among those receiving mavacamten. The trial's limited diversity and short duration raise questions about the generalizability and long-term implications of the findings. Despite the lack of approved therapies for this patient group, the study underscores the complexity of using surrogate...
info_outline
DAN-RSV: RSVpreF Vaccine for Preventing Cardiorespiratory Hospitalizations
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
The DAN-RSV trial is one of the largest individually randomized studies ever conducted, enrolling over 131,000 participants aged 60 and older to evaluate the effectiveness of the RSVpreF vaccine. Using a pragmatic design with electronic consent and national health registry data, the trial successfully met its primary objective of reducing RSV-related respiratory tract disease hospitalizations. It also achieved all key secondary endpoints, showing favorable outcomes for RSV-related and all-cause respiratory and cardiorespiratory hospitalizations. These results demonstrate the vaccine’s...
info_outline
The Role of Prevention During and After Reproduction
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
Adverse pregnancy outcomes (APOs), affecting up to 20% of pregnancies, serve as early indicators of a woman’s future cardiovascular risk and should be treated as critical markers in preventive care. Pregnancy offers a unique opportunity—a “window”—to identify and address cardiovascular vulnerabilities, making routine screening for heart health essential at every clinical encounter. Long-term monitoring beyond the postpartum period is vital, as cardiovascular risks persist and evolve over time. Improving women’s heart health requires a collaborative, lifelong approach across...
info_outline
The Role of Imaging in Cardiovascular Prevention
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
Cohort studies have provided robust data on cardiovascular risk factors, forming the basis for predictive models like the Pooled Cohort Equations and PREVENT. Clinical trials confirm that treating these risk factors effectively reduces cardiovascular events. Over the past 50 years, age-adjusted mortality from acute myocardial infarction has dropped by 89%, reflecting major progress. To advance further, we must consider integrating imaging to identify those at highest risk, using risk factors to guide treatment decisions. This dual approach could enhance precision and improve outcomes in...
info_outlineThe 2025 ACC/AHA Acute Coronary Syndrome guideline is the first major update since 2013, incorporating a decade of new evidence and clinical insights. The writing committee stayed on track and on time, reaching consensus on key recommendations, including checklist-based Class I and II interventions before discharge. They thoughtfully addressed legacy practices and controversial studies to ensure clarity and relevance. While some emerging data didn’t meet the threshold for formal inclusion, areas like discharge antiplatelet therapy, coronary imaging, and mechanical support devices were flagged as important for clinicians to monitor. The result is a practical, evidence-based tool to guide bedside decision-making.
In this interview, Drs. Roxana Mehran and Sunil V. Rao take listeners “Behind the 2025 Acute Coronary Syndrome Guidelines.”
Subscribe on Apple Podcasts | Subscribe to ACCEL